Table of Contents
- ABOUT DATAMONITOR HEALTHCARE
- About the Infectious Diseases and Respiratory pharmaceutical analysis
team
- CHAPTER 1 EXECUTIVE SUMMARY
- Datamonitor insight into the disease market
- Related reports
- CHAPTER 2 MARKET DEFINITION
- Market definition for this report
- Disease definition
- Overview of antiretroviral classes
- Nucleoside reverse transcriptase inhibitors (NRTIs)
- Non-nucleoside reverse transcriptase inhibitors
- Protease inhibitors
- Entry inhibitors and others
- CHAPTER 3 PATIENT ACQUISITION PROCESS
- Introduction
- Patient care path
- Points of influence in the patient care path
- Increasing awareness of HIV and encouraging more voluntary testing
of patients
- Choice of first-line therapy
- Decisions following treatment failure
- Factors that influence patient flow through the healthcare system
- CHAPTER 4 MARKET OVERVIEW
- Seven major markets
- Current market assessment
- Future market assessment
- Opportunities and threats
- US
- Current market assessment
- Future market assessment
- Opportunities and threats
- Japan
- Current market assessment
- Future market assessment
- Opportunities and threats
- 5 major European markets (5EU)
- Current market assessment
- Future market assessment
- Opportunities and threats
- France
- Current market assessment
- Future market assessment
- Germany
- Current market assessment
- Future market assessment
- Italy
- Current market assessment
- Future market assessment
- Spain
- Current market assessment
- Future market assessment
- UK
- Current market assessment
- Future market assessment
- Rest of World snapshot
- Current market assessment
- Opportunities and threats
- CHAPTER 5 BRAND DYNAMICS
- Overview of competitive landscape
- Drivers of brand choice
- Patient resistance profile
- Quality of life considerations
- Pill burden and dosing frequency
- Side effects
- US formulary status for leading brands
- Marketing strategies
- Promotional Spend
- Sponsorship and Public Awareness Campaigns
- Direct to consumer advertising
- Atripla is the new gold standard for newly diagnosed patients
- Truvada and Sustiva are successful first-line drugs
- Drug profile
- Product positioning
- Brand forecast to 2017
- Strategic recommendations
- Kaletra' s position as leading PI is under threat
- Drug profile
- Product positioning
- Brand forecast to 2017
- Strategic recommendations
- Reyataz to replace Kaletra as leading PI
- CASTLE results and EU approval for naÏve patients to increase uptake
- Drug profile
- Product positioning
- Brand forecast to 2017
- Strategic recommendations
- Isentress is being positioned across all lines of therapy
- Target product profile
- Development overview
- Product positioning
- Drug forecast to 2017
- Strategic recommendations
- Intelence is enabling use of NNRTIs in late-stage therapy
- Target product profile
- Development overview
- Product positioning
- Drug forecast to 2017
- Strategic recommendations
- CHAPTER 6 KEY DEVELOPERS
- Strategic overview
- Trends in corporate strategy
- Companies are pursuing first-line indication
- Gilead
- Corporate strategy
- HIV portfolio assessment
- GlaxoSmithKline
- Corporate strategy
- HIV portfolio assessment
- Tibotec
- Corporate strategy
- HIV portfolio assessment
- Porfolio assessment of other leading companies
- Sustiva' s patent expiry may put BMS' s HIV franchise at risk
- With Norvir' s patent expiry in 2014 and a lackluster pipeline,
Abbott' s position in the HIV market will diminish.
- Roche has publicly announced withdrawal from the HIV market
- Boehringer Ingelheim is heavily reliant on Viramune and Aptivus
- Merck' s strong pipeline will make it a fierce competitor in the HIV
market
- CHAPTER 7 CASE STUDIES
- Canadian HIV market overview
- Overview of the Canadian healthcare system
- All jurisdictions cover the majority of HIV drug costs in one way or
another, although the mechanism for coverage varies
- Market access for HIV drugs is ultimately determined by provincial
drug plans
- Price constraints imposed mainly through provincial listings
- Opportunities
- Rising prevalence of HIV contributes to growth of the market
- Drug approval times have declined significantly
- Threats
- Cost containment policies implemented by individual plans
- Proposals for a common national formulary to increase bargaining
powers with industry
- BIBLIOGRAPHY
- Journal papers
- Websites
- Others
- Datamonitor reports
- APPENDIX A - MARKET ASSUMPTION
- New product paunches
- Data definitions, limitations and assumptions
- Standard units
- Japanese market data
- Derivation of sales forecasts and pricing trends
- Forecast methodology
- APPENDIX B
- Contributing experts
- Report methodology
- About Datamonitor
- About Datamonitor Healthcare
- About the Infectious Diseases and Respiratory analysis team
- Disclaimer
- List of Tables
- Table 1: Key factors that influence patient flow through the healthcare
system
- Table 2: HIV sales forecasts in the 7MM ($m),, 2007-2017
- Table 3: Summary of opportunities and threats in the HIV market in the
7MM, 2007
- Table 4: US sales and growth of drug classes in the HIV market, 2007
- Table 5: HIV sales forecasts in the US ($m), 2007-2017
- Table 6: Summary of opportunities and threats in the HIV market in the
US, 2007
- Table 7: Japan sales and growth of drug classes in the HIV market, 2007
- Table 8: HIV sales forecasts for HIV in Japan ($m), 2007-2017
- Table 9: Overview of antiretroviral sales and market share in the 5EU by
class, 2007
- Table 10: HIV sales forecasts in the 5EU ($m), 2007-2017
- Table 11: Comparison of leading branded drug sales ($m) for HIV in the
seven major markets and the Rest of World (RoW), 2007
- Table 12: Formulary status in the US for leading brands in HIV, 2007
- Table 13: Marketing strategies used by different companies to promote
HIV drugs
- Table 14: Atripla: key facts, 2008
- Table 15: Sales forecast ($m) for Atripla for HIV in the 7MM, 2007-2017
- Table 16: Kaletra: key facts, 2008
- Table 17: Sales forecast ($m) for Kaletra for HIV in the 7MM, 2007-2017
- Table 18: Reyataz: key facts, 2008
- Table 19: Sales forecast ($m) for Reyataz for HIV in the 7MM, 2007-2017
- Table 20: Isentress: key facts, 2008
- Table 21: Sales forecast ($m) for Isentress for HIV in the 7MM, 2007-2017
- Table 22: Intelence: key facts, 2008
- Table 23: Sales forecast ($m) for Intelence for HIV in the 7MM, 2007-2017
- Table 24: Leading companies in the seven major markets HIV market,
2007-2017
- Table 25: Gilead portfolio assessment of HIV agents, 2008
- Table 26: GlaxoSmithKline portfolio assessment of HIV agents, 2008
- Table 27: Tibotec portfolio assessment of HIV agents, 2008
- Table 28: Portfolio analysis of other key players in the HIV market, 2007
- Table 29: AIDS cases by province/territory
- Table 30: Overview of drug coverage in Canada by province/territory, 2007
- Table 31: Comparison of Canadian prices of selected HIV drugs to US,
France and UK prices, 2007
- Table 32: Datamonitor' s launch dates for MS products in the 5EU and US,
2007-2017
- List of Figures
- Figure 1: HIV patient path
- Figure 2: HIV antiretroviral sales by class across 7MM
- Figure 3: Sales performance of the US, 5EU and Japan HIV markets, 2006-07
- Figure 4: Market share of drug classes for HIV in the 7MM, 2007 vs. 2017
- Figure 5: Adults and children estimated to be living with HIV, 2007
- Figure 6: Estimated number of people living with HIV globally, 1990-2007
- Figure 7: Estimated number of people newly infected with HIV globally,
1990-2007
- Figure 8: Overview of HIV vaccines in development, 2008
- Figure 9: US antiretroviral sales by class
- Figure 10: Market share of drug classes for HIV in the 7MM, 2007 vs. 2017
- Figure 11: Federal funding for HIV/AIDS, FY 1981-2007
- Figure 12: Total funding for the Ryan White CARE Act ($m), 1991-2006
- Figure 13: AIDS Drug Assistance Program funding
- Figure 14: Japan antiretroviral sales by class
- Figure 15: Market share of drug classes for HIV in the 7MM, 2007 vs.
2017 in Japan
- Figure 16: Trends in the number of newly reported HIV-infected people in
Japan, 1985-2006
- Figure 17: HIV cases and AIDS patients in Japan, 1985-2006
- Figure 18: AIDS cases in advanced industrial countries, by year,
1987-2001
- Figure 19: Summary of opportunities and threats in the HIV market in
Japan, 2007
- Figure 20: Europe antiretroviral sales by class
- Figure 21: Market share of drug classes for HIV in the 7MM, 2007 vs.
2017 in the 5EU
- Figure 22: Diagnosed HIV-infected persons accessing care by risk group
and ethnic group, UK
- Figure 23: UK HIV diagnoses by the two main routes of transmission, 1997
-2004
- Figure 24: HIV infections in the UK by the region they were acquired
from, 2006
- Figure 25: Summary of opportunities and threats in the 5EU market, 2008
- Figure 26: France antiretroviral sales by class, 2003-07
- Figure 27: Sales forecasts for antiretrovirals in France 2007-2017
- Figure 28: Germany antiretroviral sales by class, 2003-07
- Figure 29: Sales forecasts for antiretrovirals in Germany 2007-2017
- Figure 30: Italy antiretroviral sales by class, 2003-07
- Figure 31: Sales forecasts for antiretrovirals in Italy 2007-2017
- Figure 32: Spain antiretroviral sales by class, 2003-07
- Figure 33: Sales forecasts for antiretrovirals in Spain 2007-2017
- Figure 34: UK antiretroviral sales by class, 2003-07
- Figure 35: Sales forecasts for antiretrovirals in UK 2007-2017
- Figure 36: ROW versus seven major markets sales ($m) split for
antiretrovirals in the HIV market, 2007
- Figure 37: Annual global sales of antiretrovirals in the HIV market,
2004-07
- Figure 38: Overview of HIV prevalence, new infections and AIDS deaths by
region, 2007
- Figure 39: Overview of 10 highest-selling antiretrovirals in 2007 and
market share
- Figure 40: Type of promotional activity for Truvada and Atripla as a
percentage of total promotional spend from 2005-2007
- Figure 41: GSK' s Treat HIV website
- Figure 42: Atripla sales ($m) by country in the 7MM, 2007-2017
- Figure 43: Kaletra sales ($m) by country in the 7MM, 2007-2017
- Figure 44: Reyataz sales ($m) by country in the 7MM, 2007-2017
- Figure 45: Isentress sales ($m) by country in the 7MM, 2007-2017
- Figure 46: Intelence sales ($m) by country in the 7MM, 2007-2017
- Figure 47: Overview of the Canadian HIV market by class, 2003-07
- Figure 48: Sales of the 10 top selling HIV drugs in Canada, 2003-07
- Figure 49: Average delay between first launch in the world and launch in
each country for drugs launched between 1999 and 2003
|
Related Report
|
View Cart
